- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.09. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth | 221 | ACCESS Newswire | Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" SegmentAccess the segment here HOUSTON, TX / ACCESS Newswire / September 1, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)... ► Artikel lesen | |
| 27.08. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference | 371 | ACCESS Newswire | Video webcast now available here HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline... ► Artikel lesen | |
| 12.08. | CNS Pharmaceuticals GAAP EPS of -$0.37 misses by $0.13 | 6 | Seeking Alpha | ||
| 12.08. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation | 497 | ACCESS Newswire | Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline... ► Artikel lesen | |
| 12.08. | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 02.07. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 08.06. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment | 347 | ACCESS Newswire | Access the segment here HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative... ► Artikel lesen | |
| CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 20.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress | 435 | ACCESS Newswire | Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline... ► Artikel lesen | |
| 14.05. | CNS Pharmaceuticals reports Q1 results | 2 | Seeking Alpha | ||
| 14.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress | 326 | ACCESS Newswire | Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with... ► Artikel lesen | |
| 14.05. | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 06.05. | What's Going On With CNS Pharmaceuticals Stock On Wednesday? | 4 | Benzinga.com | ||
| 04.05. | CNS Pharmaceuticals Stock Surges 263% On Private Placement | 7 | RTTNews | ||
| 04.05. | CNS Pharmaceuticals raises $22.5 million in private placement | 3 | Investing.com | ||
| 04.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing | 606 | ACCESS Newswire | The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare PartnersProceeds expected to... ► Artikel lesen | |
| 04.05. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.04. | CNS Pharmaceuticals, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 31.03. | CNS Pharmaceuticals, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 11.03. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline | 600 | ACCESS Newswire | Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing marketsStrategic transformation... ► Artikel lesen | |
| 02.03. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team | 373 | ACCESS Newswire | Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNSNewly formed executive team is committed to execution and company... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,360 | -3,28 % | Biofrontera erhält FDA-Zulassung für Hautkrebsbehandlung | ||
| TRAWS PHARMA | 0,491 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights | Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge studyCompleted the April 2026 private... ► Artikel lesen | |
| CURIS | 0,880 | 0,00 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| GENPREX | 3,470 | 0,00 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| TVARDI THERAPEUTICS | 1,430 | +1,42 % | Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update | Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations... ► Artikel lesen | |
| ALAUNOS THERAPEUTICS | 1,205 | +0,42 % | Alaunos Therapeutics Stock Falls 17% After Public Offering Announcement | ||
| AINOS | 1,460 | -1,35 % | Ainos, Inc.: VASRO Research Highlights Ainos' New Order, Semiconductor Commercial Momentum and 1 Billion+ Chemical Dataset | Report points to front-end semiconductor orders, a $2.1 million back-end program and continued dataset expansion as key indicators of Ainos' growing commercial scale HOUSTON, TX / ACCESS Newswire /... ► Artikel lesen | |
| MATINAS BIOPHARMA | 0,161 | 0,00 % | Matinas BioPharma Holdings, Inc. - 8-K, Current Report | ||
| ENVERIC BIOSCIENCES | 1,590 | -1,85 % | Enveric receives U.S. patent allowance for psychiatric compounds | ||
| NEUPHORIA THERAPEUTICS | 3,710 | +0,27 % | Neuphoria Therapeutics Inc. - 10-K, Annual Report | ||
| SCINAI IMMUNOTHERAPEUTICS LTD | 1,540 | -1,28 % | Scinai Immunotherapeutics Ltd.: Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum | Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT JERUSALEM, Aug. 24, 2026 /PRNewswire/ - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical... ► Artikel lesen | |
| CLEARMIND MEDICINE | 0,800 | +0,08 % | Clearmind Medicine Inc.: Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. | Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and shared insights from Clearmind's clinical trial at Yale and Johns Hopkins Vancouver, Canada, Sept.... ► Artikel lesen | |
| NIKI BIOSOLUTIONS | 4,950 | +4,87 % | Niki BioSolutions, Inc.: Niki BioSolutions Accelerates Its Alzheimer's Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics | Advanced multi-omics data analysis and biostatistical expertise to sharpen target and biomarker decisions across the platform PRINCETON, N.J., and NEW HAVEN, Conn., Sept. 14, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| ABVC BIOPHARMA | 1,160 | 0,00 % | EQS-News: ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders | EQS-News: ABVC BioPharma, Inc.
/ Key word(s): Manufacturing
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares... ► Artikel lesen | |
| ARTELO BIOSCIENCES | 3,930 | -0,25 % | Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity | Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic- and Wegovy- Combining ART27.13... ► Artikel lesen |
Das Unternehmen CNS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,20 % bei einem Aktienkurs von 5,120 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CNS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.